Royalty Report: Drugs, Therapeutic, Biotechnology – Collection: 203051

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 7

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 7

Primary Industries

  • Drugs
  • Therapeutic
  • Biotechnology
  • Disease
  • Medical
  • Device
  • Supply
  • Diagnostic
  • Technical Know How

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203051

License Grant
The University hereby grants to Licensee an exclusive license under Regents Patent Rights, in jurisdictions where Regents Patent Rights exist, to make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods in the Field of Use to the extent permitted by law.
License Property
Patent Rights means The Regents interest in any of the patent applications listed to this Agreement and assigned to The Regents (Case Nos. 1999-560, 2004-331, 2006-369, 2009-271, 2009-569, and 2011-416); any continuing applications thereof including divisions; but excluding continuations-in-part except to the extent of claims entirely supported in the specification and entitled to the priority date of the parent application; any patents issuing on these applications including reissues and reexaminations; and any corresponding foreign patents or patent applications; all of which will be automatically incorporated in and added to a part of this Agreement.

Certain invention (the Inventions), generally characterized as

1)
UCLA Case No. 1999-560: “NELL-1 Enhanced Bone Mineralization”;

2)
UCLA Case No. 2004-331: “NELL1 Expression Systems and Neuroprotective Activity of NELL2”;

3)
UCLA Case No. 2006-369: “Recombinant NELL-1 & 2 Protein Production”;

4)
UCLA Case Number: 2009-271: “Recombinant NELL Protein Production”;

5)
UCLA Case No. 2009-569: “NELL-1 Isoform”, and

6)
UCLA Case No. 2011-416: “Using NELL-1 to Inhibit Osteoclasts and to Prevent, Treat Osteoporosis”

Licensed Product means any article, composition, apparatus, substance, chemical, or any other material whose manufacture, use or sale would constitute an infringement of any Valid Claim within Regents Patent Rights, or any service, article, composition, apparatus, chemical, substance, or any other material made, used, or sold by or utilizing or practicing a Licensed Method. This definition of Licensed Product also includes a service either used by Licensee, an Affiliate, or Sublicensee or provided by Licensee, an Affiliate or Sublicensee to its customers when such service requires the use of Licensed Product or performance of Licensed Method.

Licensed Method means any process or method whose use or practice would constitute an infringement of any Valid Claim within Regents Patent Rights.

Regents Patent Rights:

1999-560-1
NELL-1 Enhanced Bone Mineralization

United States Of America

09/412,297
1999-560-2
NELL -1 Enhanced Bone Mineralization

United States Of America

11/392,294
1999-560-3
Composition for Promoting Cartilage Formation or Repair Comprising a NELL Gene Product and Method of Treating …

United States Of America

11/594,510
1999-560-3
Composition for Promoting Cartilage Formation or Repair Comprising a NELL Gene Product and Method of Treating …

European Patent Office

7871373.2
1999-560-3
Composition for Promoting Cartilage Formation or Repair Comprising a NELL Gene Product and Method of Treating …

Canada

2668375
1999-560-4
NELL-1 Enhanced Bone Mineralization

United States Of America

11/713,366
1999-560-4
NELL-1 Enhanced Bone Mineralization

Canada

2679723
1999-560-6
Composition for Promoting Cartilage Formation or Repair Comprising a NELL Gene Product and Method of Treating …

United States Of America

12/700,644
1999-560-8
NELL-1 Enhanced Bone Mineralization

United States Of America

13/011,736
2004-331-2
NELL Peptide Expression Systems And Bone Formation Activity Of Nell Peptide

United States Of America

10/544,553
2004-331-2
NELL Peptide Expression Systems and Bone Formation Activity of Nell Peptide

United Kingdom

4709500.5
2004-331-2
NELL Peptide Expression Systems and Bone Formation Activity of Nell Peptide

Spain

4709500.5
2004-331-2
NELL Peptide Expression Systems and Bone Formation Activity of NELL Peptide

Germany

4709500.5
2004-331-3
Expression System of NELL Peptide

United States Of America

11/601,529
2004-331-3
Expression System of NELL Peptide

European Patent Office

7868700.1
2004-331-7
Expression System of NELL Peptide

United States Of America

12/700,630
2006-369-2
Pharmaceutical Compositions for Treating or Preventing Bone Conditions

United States Of America

11/884,525
2006-369-3
Pharmaceutical Compositions for Treating or Preventing Bone Conditions

United States Of America

12/897,397
2009-271-2
Recombinant NELL Protein Production

United States Of America

13/121,394
2009-271-2
Recombinant NELL Protein Production

United Kingdom

9819839.3
2009-271-2
Recombinant NELL Protein Production

Spain

9819839.3
2009-271-2
Recombinant NELL Protein Production

Germany

9819839.3
2009-271-2
Recombinant NELL Protein Production

France

9819839.3
2009-569-2
Isoform NELL-1 Peptide

United States Of America

13/256,931
2009-569-2
Isoform NELL-1 Peptide

European Patent Office

10756811.5
2009-569-2
Isoform NELL-1 Peptide

Canada

2756168
2009-569-3
Isoform NELL-1 Peptide

United States Of America

15/265,680

Field of Use
This agreement pertains to the drug industry.  Field of use means use in spinal fusion by local administration, osteoporosis, and long bones/extremities (trauma), and excludes use in cartilage and all other indications.

IPSCIO Record ID: 266352

License Grant
The University hereby grants to Licensee an exclusive license under University 's Patent Rights, in jurisdictions where University's Patent Rights exist, to make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods in the Field of Use to the extent permitted by law.
License Property
University's Patent Rights means The University interest in any of the patent applications listed in this Agreement and assigned to The University (Case Nos. 1999-560, 2004-331, 2006-369, 2009-271, 2009-569, 2011-416, 2015-573, 2016-631, and 2016-99D); any continuing applications thereof including divisions; but excluding continuations-in-part except to the extent of claims entirely supported in the specification and entitled to the priority date of the parent application; any patents issuing on these applications including reissues and reexaminations; and any corresponding foreign patents or patent applications; all of which will be automatically incorporated in and added to and made a part of this Agreement. The patent applications and patents included as a result of Case Nos. 2015-573, 2016-631 and 2016-99D are referred to in certain provisions of this Agreement as the “Newly Added Patent Rights” within the University's Patent Rights.

Patent No. 8,048,646 from US Application No. 12/400,715 – NELL Peptide Expression Systems And Bone Formation Activity Of Nell Peptide
Patent No. 7,807,787 from US Application No. 12/400,714 – NELL Peptide Expression Systems And Bone Formation Activity Of Nell Peptide
Application No. 09/412,297 – NELL-1 Enhanced Bone Mineralization
Application No. 11/392,294 – NELL -1 Enhanced Bone Mineralization
Application No. 11/713,366 – NELL-1 Enhanced Bone Mineralization

Licensed Product means any article, composition, apparatus, substance, chemical, or any other material whose manufacture, use or sale would constitute an infringement of any Valid Claim within University's Patent Rights, or any service, article, composition, apparatus, chemical, substance, or any other material made, used, or sold by or utilizing or practicing a Licensed Method. This definition of Licensed Product also includes a service either used by Licensee, an Affiliate, or Sublicensee or provided by Licensee, an Affiliate or Sublicensee to its customers when such service requires the use of Licensed Product or performance of Licensed Method.

Licensed Method means any process or method whose use or practice would constitute an infringement of any Valid Claim within University's Patent Rights.

Field of Use
Field of Use means use in spinal fusion by local administration, Osteoporosis, and long bones/extremities (trauma), and excludes use in cartilage and all other indications.  Osteoporosis means thinning of the bones, with reduction in bone mass, due to depletion of calcium and bone protein.

IPSCIO Record ID: 26284

License Grant
The University granted an exclusive license to several of its patents covering, among other things, enhanced Nell-1 bone mineralization. Under the license, the Licensee is permitted to make, have made, use, sell, offer for sale and import any products covered by the licensed patents in a certain field of use.
License Property
The Licensee is targeting spinal fusion as the first clinical indication and is currently in the pre-investigational device exemption (IDE) phase. The lead product, purified Nell-1 recombinant protein, is expected to be dried onto ß-tricalcium phosphate (TC”) bone void filler to produce a medical device, known as Nell-1/TCP (Nell/TCP Fusion Device). This device will be mixed with 510(k) cleared DBX® Demineralized Bone Putty recommended for use in conjunction with a cleared intervertebral body fusion device. The Nell-1/TCP Fusion Device is intended for use in lumbar spinal fusion and may have a variety of other applications such as cervical spinal fusion.
Field of Use
By a subsequent Seventh Amendment entered into on August 7, 2012, the parties modified the applicable field of use that Licensee is permitted to use the patents in, which generally comprises musculoskeletal repair and regeneration, plus some related methods of manufacture. The Nell-1/TCP Fusion Device will be comprised of a single dose vial of NELL-1 recombinant protein freeze dried onto TCP. A vial of Nell-1/TCP will be sold in a convenience kit with a diluent and a syringe of 510(k) cleared demineralized bone (“DBX® Putty”), produced by MTF. A delivery device will allow the surgeon to mix the reconstituted Nell 1/TCP with the appropriate quantity of DBX® Putty just prior to implantation.

IPSCIO Record ID: 210731

License Grant
Under the terms of the Restated License Agreement, the University have continued to grant the Company exclusive rights to develop and commercialize NELL-1 (the Licensed Product) for spinal fusion applications.
License Property
The Licensed Product is a recombinant human protein growth factor that is essential for normal bone development.

NELL-1’s powerful specific bone and cartilage forming properties are derived from the ability of NELL-1 to only target cells that exhibit an activated “master switch” to develop into bone or cartilage. NELL-1 is a function specific recombinant human protein that has been proven in laboratory bench models to recapitulate normal human growth and development to provide control over bone and cartilage regeneration.

Field of Use
Licensee has expanded its Field of Use definition beyond spine fusion within the NELL-1 license agreement with Regents. Consistent with that expansion, Licensee has entered into an exclusive license agreement with Regents for the worldwide application of the NELL-1 protein for both osteoporosis and trauma through a technology transfer. This agreement pertains to the drug industry.

IPSCIO Record ID: 7647

License Grant
The University hereby grants to Licensee an exclusive license under Patent Rights, to make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods under Licensor Patent Rights, in jurisdictions where Licensor's Patent Rights exist, in the Field of Use to the extent permitted by law.
License Property
Licensed property is generally characterized as:

NELL-1 Enhanced Bone Mineralization”“NELL-1 Enhanced Bone Mineralization”

“NELL1 Expresion Systems and Neuroprotective Activity of NELL2”

“Recombinant NELL-1 & 2 Protein Production”

Field of Use
The Field of Use means modulation of neuroectodermal, mesenchymal cell or mesoderm derivatives, including musculoskeletal and cardiovascular system growth, formation, replacement, remodeling, regeneration, or repair.

The Licensee manufactures orthobiologic products. The Licensee's protein-based technologies deliver outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

IPSCIO Record ID: 289192

License Grant
The Regents grants to Licensee a license under its rights in and to Patent Rights to make, use, Sell, offer for Sale and import Licensed Products and to use and practice the Patent Rights and Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.
License Property
Patent Rights means to the extent assigned to or otherwise obtained by The Regents, the following United States patents and patent applications and all rights thereunder:
6,589,531 – Recombinant yellow fever virus and method of use thereof
6,893,643 – Recombinant yellow fever virus and methods of use thereof

The term Patent Rights shall also mean, to the extent assigned to or otherwise obtained by The Regents, any reissues, extensions, substitutions, continuations, divisions, and continuation-inpart applications (but excluding those Valid Claims in the continuation-in-part applications that are not supported in the specification of and not entitled to the priority date of the parent application). This definition of Patent Rights excludes any rights in and to New Developments.

Licensed Product(s) means any Product, (which may include, without limitation, a Product for use or used in practicing a Licensed Method and any Product made by practicing a Licensed Method), the manufacture, use, Sale, offer for Sale or import of which, but for the license granted in this Agreement, would infringe, or contribute to, or induce the infringement of, any Patent Rights in any country were they issued at the time of the infringing activity in that country.  For the avoidance of doubt, if such Product is a component of a larger unit such as a kit, composition of matter or combination, then such kit, composition of matter or combination is deemed to be the Licensed Product for purposes of this definition.

Product means any kit, article of manufacture, composition of matter, material, compound, component or product.

Licensed Method means any process, art or method the use or practice of which, but for the license granted in this Agreement, would infringe, or contribute to, or induce the infringement of, any Patent Rights in any country were they issued at the time of the infringing activity in that country.

Field of Use
Field of Use means all uses, applications and indications relating to human health, such as diagnostic, prophylactic and therapeutic applications, including without limitation Licensee’s and any Sublicensee’s internal research and development use as required to develop such applications and all commercial uses relating to human healthcare.  All other uses are excluded.

IPSCIO Record ID: 114632

License Grant
Licensor hereby grants to Licensee and its Affiliates, subject to the terms and conditions hereof, for the Term an exclusive license, with the right to sublicense, under the Patent Rights, to make, have made, use, have used, sell, have sold, offer to sell, have offered for sale, import, have imported, develop and commercialize Licensed Products and to practice the Licensed Processes in the Field in the Territory.
License Property
Licensed Product shall mean (i) any product the import, manufacture, use, offer for sale or sale of which, but for the licenses granted herein, would infringe a Valid Claim of the Patent Rights or (ii) any product made or used in accordance with or by means of Licensed Processes.

Patent Rights:
Process and compositions for peptide, protein and peptidomimetic synthesis – United States of America Issued (US 6,977,150: Corresponding Appl. No. 10/057,783)

Process and compositions for peptide, protein and peptidomimetic synthesis – Australia Issued (Patent No. 2002255488)

Process and compositions for peptide, protein and peptidomimetic synthesis – Switzerland Issued (Patent No. 1356036; Corresponding Appl. No. 2724888.9)

Process and compositions for peptide, protein and peptidomimetic synthesis – Germany Issued (Patent No. 60226411.1-08; Corresponding Appl. No. 2724888.9)

Process and compositions for peptide, protein and peptidomimetic synthesis – European Patent Office Issued (EP 1 356 036 B1; Corresponding Appl. No. 2724888.9)

Process and compositions for peptide, protein and peptidomimetic synthesis – France Issued (Patent No. 1356036; Corresponding Appl. No. 2724888.9)

Process and compositions for peptide, protein and peptidomimetic synthesis – United Kingdom Issued (Patent No. 1356036; Corresponding Appl. No. 2724888.9)

Process and compositions for peptide, protein and peptidomimetic synthesis – Ireland Issued (Patent No. 1356036; Corresponding Appl. No. 2724888.9)

Pending Applications:
Process and compositions for peptide, protein and peptidomimetic synthesis – Canada Pending Appl. No. 2,435,812

Process and compositions for peptide, protein and peptidomimetic synthesis – Japan Pending Appl. No. 2002-559580

Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.